Video

Blake A. Morrison Discusses the Excitement in Myeloma Research

Author(s):

Blake A. Morrison

Blake A. Morrison discusses the recent excitement in myeloma research.

Blake A. Morrison, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses the recent excitement in myeloma research.

Morrison touches on the approvals of Empliciti (elotuzumab), Ninlaro (ixazomib) and Darzalex (daratumumab), as well as the research into CAR T cell immunotherapy.

Read more of our coverage from the 2015 ASH Annual Meeting

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Related Content
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of ronald.
June 25th 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
June 5th 2025

Being in the Present Moment With Multiple Myeloma

Ronald Chin
I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor.
Grace Allison, B.S.N., RN, OCN, RN-BC, and Erin Mensching, RN-B.S.N., OCN
May 18th 2025

Providing Care and Listening With Compassion During Cancer

Grace Allison, B.S.N., RN, OCN, RN-BC